Androgenetic alopecia (AGA) Skin and Connective Tissue Diseases
Conditions
Interventions
Participants were assigned to treatment groups at the discretion of the treating physicians. It was determined based on clinical judgment and patient suitability for the interventions.
Intervention A
Sponsors
Zydus Healthcare Ltd
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Male or female participants aged 18 years and above 2. Participants with a confirmed diagnosis of Androgenetic Alopecia (AGA) 3. Participants eligible to receive topical Minoxidil 5% solutions for the treatment of AGA at the discretion of the treating physician 4. Participants willing to provide written informed consent 5. Participants who have not received any topical or systemic treatment for hair loss prior to enrollment in the study
Exclusion criteria
Exclusion criteria: 1. Participants with known hypersensitivity to Minoxidil or any of the ingredients in the test products (MpowerTM or plain minoxidil) 2. Pregnant or breastfeeding females or those planning a pregnancy during the study period 3. Participants with any medical condition that contraindicates the use of minoxidil as determined by the treating physician 4. Participants currently using any other topical or systemic treatments for hair loss 5. Participants with scalp conditions such as inflammation, erythema, infection, irritation, or pain at the application site
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Hair diameter measured using trichoscopic analysis at baseline, 2 and 4 months 2. Terminal hair density evaluated through trichoscopic analysis at baseline, 2 and 4 months (measured in hairs/cm²) 3. Total hair density: assessed via trichoscopy at baseline, 2 and 4 months (measured in hairs/cm²) 4. Vellus hair percentage measured using trichoscopy at baseline, 2 and 4 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Subject satisfaction assessed using the Subject Satisfaction Questionnaire (SSQ) at the end of 4 months 2. Tolerability evaluated based on investigator and participant feedback at 4 months using a four-point scale (excellent, good, fair, poor) 3. Compliance calculated from daily entries in participant diaries, reviewed at 2 and 4 months | — |
Countries
India
Contacts
Public ContactPrachi Sharma
Outcome results
None listed